The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. (December 2014)

• Record Type: Journal Article
• Authors: Henick, Brian S; Herbst, Roy S; Goldberg, Sarah B
• Is Part Of: Expert opinion on therapeutic targets. Volume 18:Number 12(2014:Dec.)
• Page Start: 1407
• Page End: 1420
• Publication Date: 2014-12
• Subjects: Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1517/14728222.2014.955794
• Languages: English
• ISSNs: 1744-7631

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold> <italic>Introduction:</italic> </bold> Immunotherapy is emerging as a powerful approach in cancer treatment. Preclinical data predicted the antineoplastic effects seen in clinical trials of programmed death-1 (PD-1) pathway inhibitors, as well as their observed toxicities. The results of early clinical trials are extraordinarily promising in several cancer types and have shaped the direction of ongoing and future studies.</p> <p> <bold> <italic>Areas covered:</italic> </bold> This review describes the biological rationale for targeting the PD-1 pathway with monoclonal antibodies for the treatment of cancer as a context for examining the results of early clinical trials. It also surveys the landscape of ongoing clinical trials and discusses their anticipated strengths and limitations.</p> <p> <bold> <italic>Expert opinion:</italic> </bold> PD-1 pathway inhibition represents a new frontier in cancer immunotherapy, which shows clear evidence of activity in various tumor types including NSCLC and melanoma. Ongoing and upcoming trials will examine optimal combinations of these agents, which should further define their role across tumor types. Current limitations include the absence of a reliable companion diagnostic to predict likely responders, as well as lack of data in early-stage cancer when treatment has the potential to increase cure rates.</p> </abstract>